CTOs on the Move

NPS Pharmaceuticals

www.npsp.com

 
NPS Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.npsp.com
  • 550 Hills Dr
    Bedminster, NJ USA '07921
  • Phone: 908.450.5300

Executives

Name Title Contact Details

Similar Companies

Opentrons Labworks

Opentrons Labworks, Inc., is a disruptive life science company leveraging its integrated lab platform to supercharge the pace of innovation in research and healthcare. Opentrons Labworks is the parent company to business units Opentrons Robotics and Neochromosome. Through Opentrons Robotics, thousands of institutions are automating R&D operations with flexible, easy-to-use liquid handling lab robots. Through Neochromosome, biopharma and biotech at large can benefit from our world-class genome-scale cell engineering solutions. Opentrons Robotics, a business unit of Opentrons Labworks, Inc., is the industry leader in flexible, user-friendly automation for life science labs. Our open-source ecosystem offers the scientific community the tools they need to automate experiments, share protocols and reproduce each other`s results. Opentrons robots can be found in thousands of academic, biopharma, synthetic biology and clinical research labs in more than 40 countries.

Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tranquis Therapeutics

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.

Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.